IL17A and psoriasis: There were no significant differences in the rate of COVID-19 mortality between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics in the confirmed cases group (RR: 1.30; 95% CI: 0.38-4.44; P = 0.67) and in the suspected cases group (RR: 3.88; 95% CI: 0.67-22.54; P = 0.13), respectively (Figure 5C).